Quintrio
Home

ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES

Align Technology Inc

ALGN

Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling a lion's share of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. Invisalign treats over 2 million cases annually, or roughly 10% of all orthodontic cases and has treated over 20 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.

Last trade $163.78
Day change -$2.20 (-1.33%)
Day range $162.47 – $166.89
Volume 441,584
Market cap $11.70B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$11.7B
Price / earnings
23.79×
Price / book
2.72×
Price / sales
2.81×
EV / sales
2.54×
EV / EBITDA
11.6×

Profitability

Earnings per share
$6.98
Return on assets
7.54%
Return on equity
11.42%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
1.42×
Quick ratio
1.31×
Cash ratio
0.6×

Cash flow

Price / cash flow
15.6×
Price / free cash flow
19.42×
Free cash flow
$602.5M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ALGN, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$1.01B$1.06B$1.04B$1.05B$995.69M$1.01B$979.26M$995.22M
Cost of revenue$317.29M$298.76M$303.5M$363.97M$356.49M$304.33M$299.15M$298.28M
Gross profit$697.47M$757.43M$736.59M$683.59M$639.2M$708.12M$680.11M$696.94M
Selling, general and administrative$410.55M$462.67M$465.34M$441.68M$417.8M$448.69M$447.63M$424.97M
Research and development$93.87M$102.03M$98.66M$83.04M$93.28M$96.4M$97.2M$94.88M
Total operating expenses$528.31M$603.42M$594.63M$528.26M$542.9M$545.08M$549.01M$552.79M
Operating income$169.16M$154.01M$141.96M$155.32M$96.3M$163.03M$131.1M$144.15M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes$170.07M$148.69M$148.89M$176.6M$94.73M$173.52M$140.44M$140.78M
Income taxes$35.03M$40.4M$36.12M$40.84M$37.98M$48.91M$47.21M$36.97M
Net income$135.04M$108.29M$112.77M$135.76M$56.75M$124.61M$93.23M$103.81M
Net income attributable to common shareholders$135.04M$108.29M$112.77M$135.76M$56.75M$124.61M$93.23M$103.81M
EBITDA$225.84M$194.14M$229.14M$260.87M$183.84M$203.61M$174.43M$215.22M
Basic earnings per share$1.90$1.51$1.58$1.89$0.78$1.72$1.27$1.40
Diluted earnings per share$1.90$1.51$1.57$1.89$0.78$1.72$1.27$1.39

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Should You Continue to Hold ALGN Stock in Your Portfolio?

Align Technology has gained 25.4% over the past year, outperforming the S&P 500, driven by Invisalign portfolio expansion into younger patients and complex cases, plus strategic DSO partnerships. However, the stock faces headwinds from currency volatility and intense competition from traditional braces and lower-priced clear aligner alternatives. The company holds a Zacks Rank #3 (Hold) with 2026 EPS estimates revised down 1.5% to $11.12.

Zacks Investment Research

ALGN Q3 Earnings & Revenues Beat, '26 Sales View Down, Stock Falls

Align Technology (ALGN) reported Q3 2026 earnings of $2.80 per share (up 7.3%) and revenues of $1.01 billion (up 1.9%), both beating estimates. Clear Aligner shipments grew 6.6% to a record level, supported by strong international growth and improved doctor utilization. However, Systems revenues declined 7.6% due to pricing pressure from lower-priced scanner configurations. The company cut its 2026 revenue guidance to $4.11-$4.13 billion, citing softer Systems and Services expectations and lower Clear Aligner ASP assumptions, causing shares to fall 0.7% after-hours.

Zacks Investment Research

Will Align Technology (ALGN) Beat Estimates Again in Its Next Earnings Report?

Align Technology, maker of the Invisalign tooth-straightening system, is positioned to potentially beat earnings estimates in its upcoming October 28, 2026 report. The company has a strong track record of beating estimates with an average surprise of 8.64% over the past two quarters. With a positive Earnings ESP of +1.23% combined with a Zacks Rank #3 (Hold), analysts suggest another earnings beat is likely, as stocks with this combination historically beat consensus estimates nearly 70% of the time.

Zacks Investment Research

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

The article highlights two medical stocks with positive Earnings Surprise Prediction (ESP) metrics that could outperform expectations: Align Technology (ALGN) with a +1.23% ESP ahead of October 28 earnings, and Iovance Biotherapeutics (IOVA) with a +22.22% ESP before November 5 earnings. Both stocks hold a Zacks Rank #3 (Hold) rating, and positive ESP combined with favorable rankings historically produce positive surprises 70% of the time.

Zacks Investment Research

XRAY's Q2 Earnings Beat Meets Steady Guidance and Margin Pressure

DENTSPLY SIRONA (XRAY) exceeded Q2 earnings and revenue estimates with adjusted EPS of 52 cents versus 36 cents consensus, though revenues fell 4.1% year-over-year. The company maintained full-year 2026 guidance of $3.5-3.6B in sales and $1.40-1.50 adjusted EPS. Wellspect Healthcare grew 7.1%, but three dental segments declined, with tariff pressures and lower volumes constraining operating margins. Free cash flow improved to $55M from $16M year-ago.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.